LCN2 and myeloproliferative neoplasm: To translate our findings to MPN patient samples, we incubated PBMCs of three PV patients, carrying the JAK2V617F mutation, for 24 h with Kira-6 or JNK-IN-8 and analyzed changes in LCN2 mRNA expression (Figure 4E).